Pharmaceutical

Boehringer Ingelheim advances weight loss drug to Phase III trials

Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.

Aug 18, 2023 - 20:00
Boehringer Ingelheim advances weight loss drug to Phase III trials
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
Read the original article

Tags:

Previous Article

AbbVie achieves win for migraine prevention drug Aquipta in Europe

Next Article

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Starting breast cancer screening at 40 saved my life

Opinion: Starting breast cancer screening at 40 saved m...

May 17, 2023

STAT+: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again

STAT+: Gene therapy makers wonder if they can make a pr...

Oct 4, 2023

Opinion: Listen: The true costs of mediocre insurance plans for medical students

Opinion: Listen: The true costs of mediocre insurance p...

Nov 15, 2023